Protective effect of rhGLP-1 (7-36) on brain ischemia/reperfusion damage in diabetic rats

Brain Research

Volumn 1602, Issue C, 2015, Pages 153-159

  Zhao, Libo ^a   Xu, Jia ^b   Wang, Qian ^a   Qian, Zhonglian ^c   Feng, Wanyu ^a   Yin, Xiaoxing ^d   Fang, Yi ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b Hunan Provincial Mawangdui Hospital   (China)

^c Department of Pharmacy ^*  (China)

^d XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Brain ischemia reperfusion; Diabetic rats; GLP 1; Oxidative stress

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUTATHIONE PEROXIDASE; INDUCIBLE NITRIC OXIDE SYNTHASE; MALONALDEHYDE; NIMODIPINE; NITRIC OXIDE SYNTHASE; SUPEROXIDE DISMUTASE; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE 1 (7-36); GLUCOSE BLOOD LEVEL; NEUROPROTECTIVE AGENT; NOS2 PROTEIN, RAT; NOS3 PROTEIN, RAT; PEPTIDE FRAGMENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; BRAIN ISCHEMIA; CONTROLLED STUDY; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; LIPID DIET; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPATHY; NEUROPROTECTION; NITROSATIVE STRESS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ANIMAL; BRAIN; CEREBRAL ARTERY DISEASE; DIABETES MELLITUS, EXPERIMENTAL; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; RANDOMIZATION; SEVERITY OF ILLNESS INDEX; SPRAGUE DAWLEY RAT;

RATTUS;

ANIMALS; BLOOD GLUCOSE; BRAIN; BRAIN ISCHEMIA; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCAGON-LIKE PEPTIDE 1; GLUTATHIONE PEROXIDASE; HYPOGLYCEMIC AGENTS; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; MALONDIALDEHYDE; NEUROPROTECTIVE AGENTS; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; PEPTIDE FRAGMENTS; RANDOM ALLOCATION; RATS, SPRAGUE-DAWLEY; REPERFUSION INJURY; SEVERITY OF ILLNESS INDEX; SUPEROXIDE DISMUTASE;

EID: 84928017886     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2015.01.014     Document Type: Article

References (29)

1. Chan, P.H., 2001. Reactive oxygen radicals in signaling and damage in the ischemic brain. J. Cereb. Blood Flow Metab. 21, 2-14.
2. Chen, H., Song, Y.S., Chan, P.H., 2009. Inhibition of NADPH oxidase is neuroprotective after ischemia-reperfusion. J. Cereb. Blood Flow Metab. 29, 1262-1272.
3. Choi, S.H., Lee, H.C., 2011. Long-term, antidiabetogenic effects of GLP-1 gene therapy using a double-stranded, adeno-associated viral vector. Gene. Ther. 18, 155-163.
4. D'Alessio, D.A., Prigeon, R.L., Ensinck, J.W., 1995. Enteral enhancement of glucose disposition by both insulin-dependent and insulin-independent processes. A physiological role of glucagon-like peptide I. Diabetes 44, 1433-1437.
5. Diamant, M., Van Gaal, L., Guerci, B., Stranks, S., Han, J., Malloy, J., Boardman, M.K., Trautmann, M.E., 2014. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial. Lancet Diabetes Endocrinol. 2, 464-473.
6. Dunphy, J.L., Taylor, R.G., Fuller, P.J., 1998. Tissue distribution of rat glucagon receptor and GLP-1 receptor gene expression. Mol. Cell Endocrinol. 141, 179-186.
7. Feigin, V.L., Forouzanfar, M.H., Krishnamurthi, R., Mensah, G.A., Connor, M., Bennett, D.A., Moran, A.E., Sacco, R.L., Anderson, L., Truelsen, T., O'Donnell, M., Venketasubramanian, N., Barker-Collo, S., Lawes, C.M.,Wang, W., Shinohara, Y.,Witt, E., Ezzati,M., Naghavi, M., Murray, C., 2014. Global and regional burden of stroke during 1990-2010: findings from the global burden of disease study 2010. Lancet 383, 245-254.
8. Hausenloy, D.J., Whittington, H.J., Wynne, A.M., Begum, S.S., Theodorou, L., Riksen, N., Mocanu, M.M., Yellon, D.M., 2013. Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner. Cardiovasc. Diabetol. 12, 154.
9. Kissela, B.M.,Khoury, J.,Kleindorfer,D., Woo, D., Schneider, A.,Alwell, K., Miller, R., Ewing, I., Moomaw, C.J., Szaflarski, J.P., Gebel, J., Shukla, R., Broderick, J.P., 2005. Epidemiology of ischemic stroke in patients with diabetes: the greater Cincinnati/Northern Kentucky Stroke Study. Diabetes Care 28, 355-359.
10. Lawes, C.M., Parag, V., Bennett, D.A., Suh, I., Lam, T.H., Whitlock, G., Barzi, F., Woodward, M., 2004. Blood glucose and risk of cardiovascular disease in the Asia Pacific region. Diabetes Care. 27, 2836-2842.
11. Lee, C.H., Yan, B., Yoo, K.Y., Choi, J.H., Kwon, S.H., Her, S., Sohn, Y., Hwang, I.K., Cho, J.H., Kim, Y.M., Won, M.H., 2011. Ischemia-induced changes in glucagon-like peptide-1 receptor and neuroprotective effect of its agonist, exendin-4, in experimental transient cerebral ischemia. J. Neurosci. Res. 89, 1103-1113.
12. Li, Y., Perry, T., Kindy,M.S., Harvey, B.K., Tweedie, D., Holloway, H.W., Powers, K., Shen, H., Egan, J.M., Sambamurti, K., Brossi, A., Lahiri, D.K., Mattson, M.P., Hoffer, B.J., Wang, Y., Greig, N.H., 2009. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc. Natl. Acad. Sci. U. S. A. 106, 1285-1290.
13. Longa, E.Z., Weinstein, P.R., Carlson, S., Cummins, R., 1989. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 20, 84-91.
14. Lund, A., Knop, F.K., Vilsboll, T., 2014. Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities. Eur. J. Intern. Med. 25, 407-414.
15. Ma, X., Guan, Y., Hua, X., 2014. Glucagon-like peptide 1-potentiated insulin secretion and proliferation of pancreatic beta-cells. J. Diabetes.
16. Meier, J.J., Gethmann, A., Nauck, M.A., Gotze, O., Schmitz, F., Deacon, C.F., Gallwitz, B., Schmidt, W.E., Holst, J.J., 2006. The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans. Am. J. Physiol. Endocrinol. Metab. 290, E1118-E1123.
17. Moskowitz, M.A., Lo, E.H., Iadecola, C., 2010. The science of stroke: mechanisms in search of treatments. Neuron. 67, 181-198.
18. Perry, T., Holloway, H.W., Weerasuriya, A., Mouton, P.R., Duffy, K., Mattison, J.A., Greig, N.H., 2007. Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp. Neurol. 203, 293-301.
19. Salling, H.K., Dohler, K.D., Engstrom, T., Treiman, M., 2012. Postconditioning with curaglutide, a novel GLP-1 analog, protects against heart ischemia-reperfusion injury in an isolated rat heart. Regul. Pept. 178, 51-55.
20. Sato, K., Kameda, M., Yasuhara, T., Agari, T., Baba, T., Wang, F., Shinko, A., Wakamori, T., Toyoshima, A., Takeuchi, H., Sasaki, T., Sasada, S., Kondo, A., Borlongan, C.V., Matsumae, M., Date, I., 2013. Neuroprotective effects of liraglutide for stroke model of rats. Int. J. Mol. Sci. 14, 21513-21524.
21. Silvestrelli, G., Corea, F., Paciaroni, M., Milia, P., Palmerini, F., Parnetti, L., Gallai, V., 2002. The Perugia hospital-based stroke registry: report of the 2nd year. Clin. Exp. Hypertens. 24, 485-491.
22. Srinivasan, K., Viswanad, B., Asrat, L., Kaul, C.L., Ramarao, P., 2005. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol. Res. 52, 313-320.
23. Tajes, M., Ill-Raga, G., Palomer, E., Ramos-Fernandez, E., Guix, F.X., Bosch-Morato, M., Guivernau, B., Jimenez-Conde, J., Ois, A., Perez-Asensio, F., Reyes-Navarro, M., Caballo, C., Galan, A.M., Alameda, F., Escolar, G., Opazo, C., Planas, A., Roquer, J., Valverde, M.A., Munoz, F.J., 2013. Nitro-oxidative stress after neuronal ischemia induces protein nitrotyrosination and cell death. Oxid Med. Cell Longev 2013, 826143.
24. Teramoto, S., Miyamoto, N., Yatomi, K., Tanaka, Y., Oishi, H., Arai, H., Hattori, N., Urabe, T., 2011. Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia. J. Cereb. Blood Flow Metab. 31, 1696-1705.
25. Towfighi, A., Markovic, D., Ovbiagele, B., 2012. Current national patterns of comorbid diabetes among acute ischemic stroke patients. Cerebrovasc. Dis. 33, 411-418.
26. Wardlaw, J.M., Murray, V., Berge, E., Del, Z.G., Sandercock, P., Lindley, R.L., Cohen, G., 2012. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet 379, 2364-2372.
27. WHO publishes definitive atlas on global heart disease and stroke epidemic, 2004. Indian J. Med. Sci. 58, 405-406.
28. Ying, W., Xiong, Z.G., 2010. Oxidative stress and NAD+ in ischemic brain injury: current advances and future perspectives. Curr. Med. Chem. 17, 2152-2158.
29. Zhao, L.R., Spellman, S., Kim, J., Duan, W.M., McCarthy, J.B., Low, W.C., 2005. Synthetic fibronectin peptide exerts neuroprotective effects on transient focal brain ischemia in rats. Brain Res. 1054, 1-8.